The Science section contains AAN resources that are relevant to the academic neurologist and to those who follow scientific developments in neurology, whether basic, translational, or purely clinical.
The site contains information regarding AAN scientific awards and training grants, news and resources related to the NINDS, and information related to the AAN Science Committee and its role in planning the scientific aspects of the AAN Annual Meeting.
The abstracts from the AAN Annual Meeting in San Diego were published online only this year, and can now be viewed.
The 2013 plenary session presentations are now available through the Annual Meeting On Demand website. Please visit http://aanplenary.cmeoncall.com/login to access presentations from any of the seven plenary sessions.
The Emerging Science abstracts presented at the 2013 AAN Annual Meeting are available.
The 2013 AAN Annual Meeting abstracts are now available through iPosters. iPosters provides users the opportunity to view abstracts that have been uploaded by their authors in an interactive, fully searchable database with the ability to magnify the abstract content for detailed viewing, contact the author directly with comments and/or questions, bookmark abstracts for easy access on return visits, and much more.
The scientific abstracts that will be presented at the 2013 AAN Annual Meeting are now available for viewing.
2012 Annual Meeting Abstracts
Watch for Emails Announcing Reviews of New MS Drugs
The AAN and its Multiple Sclerosis Section, led by Section Chair Robert P. Lisak, MD, FAAN, are working with a task force including the MS Coalition to make neurologists and the public aware of the known benefits and risks of newly emerging, FDA-approved medications for multiple sclerosis. AAN members will be alerted by email when reports on new medications are posted on the MS Coalition website.
This task force—dubbed the Multiple Sclerosis Emerging Therapies Collaborative—has established a dedicated rapid-response website that will provide information on new therapies as they emerge. The content is tailored to both clinicians and the general public, to facilitate effective communication and medical decision making. The AAN and MS Coalition members all have a stake in ensuring their constituencies receive the most accurate drug information, given there are a large number of competing information sources.
Review of New Drug Dextromethorphan Hydrobromide and Quinidine Sulfate to Treat PBA Available
The Multiple Sclerosis Emerging Therapies Collaborative has published information sheets on the multiple sclerosis medication dextromethorphan hydrobromide and quinidine sulfate (DM/QS, also known as Nuedexta). The medication is approved to treat pseudobulbar affect (PBA). AAN members can access the sheets, which include known benefits and risks, as well as answers to commonly asked questions, at www.ms-coalition.org/EmergingTherapies.
The content is tailored to suit both clinicians and the public to facilitate effective communication and medical decision making. The AAN and MS Coalition members all have a stake in ensuring their constituencies receive the most accurate drug information, given there are a large number of competing information sources.
For more information, contact firstname.lastname@example.org.